164 related articles for article (PubMed ID: 35695074)
1. Facial erythema in patients with atopic dermatitis treated with Dupilumab - a descriptive study of morphology and Aetiology.
Ahn J; Lee DH; Na CH; Shim DH; Choi YS; Jung HJ; Simpson EL
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2140-2152. PubMed ID: 35695074
[TBL] [Abstract][Full Text] [Related]
2. Facial and neck erythema associated with dupilumab treatment: A systematic review.
Jo CE; Finstad A; Georgakopoulos JR; Piguet V; Yeung J; Drucker AM
J Am Acad Dermatol; 2021 May; 84(5):1339-1347. PubMed ID: 33428978
[TBL] [Abstract][Full Text] [Related]
3. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab facial redness: histologic characterization on a series of four cases.
Dybała A; Sernicola A; Gomes V; Carnicelli G; Muharremi R; Grieco T
Immunotherapy; 2022 Mar; 14(4):183-188. PubMed ID: 34933583
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab facial redness: Clinical characteristics and proposed treatment in a cohort.
Ordóñez-Rubiano MF; Casas M; Balaguera-Orjuela V
Dermatol Ther; 2021 Nov; 34(6):e15140. PubMed ID: 34549488
[TBL] [Abstract][Full Text] [Related]
6. Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease.
Ferrucci S; Angileri L; Tavecchio S; Fumagalli S; Iurlo A; Cattaneo D; Marzano AV; Maronese CA
J Dermatolog Treat; 2022 Aug; 33(5):2587-2592. PubMed ID: 35261333
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
8. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series.
de Wijs LEM; Nguyen NT; Kunkeler ACM; Nijsten T; Damman J; Hijnen DJ
Br J Dermatol; 2020 Oct; 183(4):745-749. PubMed ID: 31749159
[TBL] [Abstract][Full Text] [Related]
9. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis.
Narla S; Silverberg JI; Simpson EL
J Am Acad Dermatol; 2022 Mar; 86(3):628-636. PubMed ID: 34126094
[TBL] [Abstract][Full Text] [Related]
10. Observation of the clinical features of dupilumab-associated facial erythema.
Wu H; Zhang W; Wu Z; Shen Y; Zhang L; Yang M; Ren Y; Mao F
Postepy Dermatol Alergol; 2023 Dec; 40(6):741-746. PubMed ID: 38282880
[TBL] [Abstract][Full Text] [Related]
11. Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis.
Yamane MLM; Belsito DV; Glass LRD
Orbit; 2019 Oct; 38(5):390-394. PubMed ID: 30628518
[TBL] [Abstract][Full Text] [Related]
12. Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study.
Gu C; Wu Y; Luo Y; Wang S; Yin H; Gao Y; Wang C; Yao X; Li W
J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):1064-1073. PubMed ID: 35344634
[TBL] [Abstract][Full Text] [Related]
13. Rosacea associated with dupilumab therapy.
Heibel HD; Hendricks AJ; Foshee JP; Shi VY
J Dermatolog Treat; 2021 Feb; 32(1):114-116. PubMed ID: 31132923
[No Abstract] [Full Text] [Related]
14. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
[TBL] [Abstract][Full Text] [Related]
17. Facial dermatoses and use of protective mask during Covid-19 pandemic: A clinical and psychological evaluation in patients affected by moderate-severe atopic dermatitis under treatment with dupilumab.
Vanessa M; Elia E; Federica V; Edoardo C; Chiara A; Francesca G; Paola S
Dermatol Ther; 2022 Jul; 35(7):e15573. PubMed ID: 35535633
[TBL] [Abstract][Full Text] [Related]
18. Overview of use, efficacy, and safety of dupilumab in complex patients: a retrospective, case-series study from a large, urban academic center.
Lukac D; Pagani K; McGee JS
Arch Dermatol Res; 2023 Aug; 315(6):1777-1781. PubMed ID: 35716185
[TBL] [Abstract][Full Text] [Related]
19. Experience using dupilumab for pediatric atopic dermatitis at a tertiary care c enter: Inadequate response and adverse events.
McKenzie PL; Rangu S; Treat JR; Castelo-Soccio L
Pediatr Dermatol; 2021 Sep; 38(5):1178-1184. PubMed ID: 34515353
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
